10-Q quarterly report · filed Nov 6, 2026

Allogene Therapeutics, Inc. (ALLO) Q3 2026 10-Q Quarterly Report

Short answer

Allogene Therapeutics, Inc. (ALLO) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$50M.

Q3 2026 key financials · XBRL

Revenue
$0
−100.0% QoQ
Net income
−$50M
−21.7% YoY · −18.0% QoQ
EPS (diluted)
−$0.14
+26.3% YoY · −16.7% QoQ

Source: XBRL data from the Allogene Therapeutics, Inc. (ALLO) Q3 2026 10-Q on SEC EDGAR. USD.

Allogene Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, versus $0 YoY, with revenue generated exclusively from Overland licensing
  • Net loss $50.4M, versus $41.4M YoY, operating expenses $54.8M versus $44.9M
  • Research and development $41.9M, up $10.8M YoY, driven by cema-cel development and manufacturing reactivation
  • Cash, equivalents and investments $388.9M, runway into Q1 2029, operating cash use $81.0M year to date
  • Capital deployment: $187.9M April offering proceeds and $20.7M ATM proceeds, ALPHA3 enrollment expected complete by end-2027

Risk Factors

  • Newly added risk: CFO retirement effective November 6, 2026, alongside CEO transition and interim CMO role
  • Most material update: FCA arm discontinued after Grade 5 SAE, with continued patient follow-up potentially triggering regulatory actions
  • Regulatory risk: EU GDPR breaches could incur fines up to €20,000,000 or 4% of annual total revenue
  • Near-term clinical risk: ALPHA3 enrollment delays from anticipated high MRD screen-failure rates
  • Financial risk: $388.9 million in cash and investments as of September 30, 2026, with substantial additional financing required

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Allogene Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.